HHS42 CFR Part 2

42 CFR Part 2 Patient Consent (42 CFR 2.31)

Required elements for written consent to disclose SUD treatment records under Part 2, including the prohibition on redisclosure notice.

Primary source

42 CFR 2.31 — eCFR

https://www.ecfr.gov/current/title-42/chapter-I/subchapter-A/part-2/subpart-C/section-2.31

Verified May 23, 2026 · This is the authoritative regulator URL. The summary below is a research aid; the linked source controls.

42 CFR 2.31 sets the required content for written consent to disclose Part 2 records.

The consent must include: the name(s) of the Part 2 program(s) permitted to disclose; the name(s) or general designation of the person(s) or organization(s) to whom the disclosure may be made; the name of the patient; how much and what kind of information is to be disclosed (including amount and kind); the purpose of disclosure; the patient's signature; the date signed; a statement of revocation right; and a date, event, or condition on which the consent expires.

Each disclosure of Part 2-protected information must be accompanied by a written statement informing the recipient that the information is protected by Part 2, that the recipient is generally prohibited from making any further disclosure unless permitted under Part 2, and that violation can result in criminal penalties.

The 2024 Final Rule allows a single consent to authorize disclosures for all future TPO purposes — a major operational change. Practices subject to Part 2 should refresh consent forms to take advantage of the broader TPO authorization while preserving the redisclosure notice on every outbound transmission.

Use this in your workspace

D3rx assembles the documentation linked to this regulation, walks the practical decisions in plain English, and stores the artifacts against the .gov sources cited above. It is an administrative research aid, not a substitute for counsel.

Related regulations

Authored by D3rx

D3rx is a healthcare-billing and compliance research aid maintained by D3rx Inc. Articles are drafted by an LLM (Anthropic Claude) against primary HHS, OCR, CMS, eCFR, NIST, and state-regulator publications, and reviewed for restraint and source fidelity by the D3rx team.

Reviewer status: a named credentialed reviewer (CHC, CHPC, or healthcare attorney) is being engaged. Until that engagement is finalized, this page does not claim credentialed review.

Last reviewed May 23, 2026 · Citation verified May 23, 2026

Research aid, not legal advice. This summary is an administrative research aid prepared by D3rx. It does not certify compliance, provide legal advice, replace counsel, or guarantee an audit outcome. For authoritative regulatory text follow the primary source link at the top of this page. The practice remains responsible for reviewing, adopting, and maintaining its compliance program.